Nectar Life Sciences is a NYC-based allergy-focused healthcare company that will operate the consumer-facing Nectar brand. Its platform leverages data and clinical research to deliver personalized allergy care aimed at treating the root cause of allergies and providing long-lasting relief. The company combines virtual care and physical clinics to target environmental, pet, and food allergies, as well as eczema and asthma. Its vertically integrated operations power telehealth experiences alongside a licensed compounding pharmacy to create proprietary, personalized treatments. Founder and CEO Kenneth Chahine, Ph.D., leads the company. Nectar raised $8m in seed funding to continue developing proprietary and personalized solutions ahead of a nationwide launch in the coming months.

Total raised

$8M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2022